{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:58Z","timestamp":1790985658501,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1016\/j.jconrel.2011.11.019","type":"journal-article","created":{"date-parts":[[2011,12,2]],"date-time":"2011-12-02T14:10:40Z","timestamp":1322835040000},"page":"245-253","source":"Crossref","is-referenced-by-count":58,"title":["Therapeutic efficacy of a lipid-based prodrug of mitomycin C in pegylated liposomes: Studies with human gastro-entero-pancreatic ectopic tumor models"],"prefix":"10.1016","volume":"160","author":[{"given":"Alberto","family":"Gabizon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmine","family":"Amitay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Tzemach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Gorin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilary","family":"Shmeeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Zalipsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.jconrel.2011.11.019_bb0005","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/1074-5521(95)90120-5","article-title":"Mitomycin C: small, fast and deadly (but very selective)","volume":"2","author":"Tomasz","year":"1995","journal-title":"Chem. Biol."},{"issue":"10\u201311","key":"10.1016\/j.jconrel.2011.11.019_bb0010","first-page":"501","article-title":"Mitomycin C: a prototype bioreductive agent","volume":"6","author":"Sartorelli","year":"1994","journal-title":"Oncol. Res."},{"issue":"3 Suppl 4","key":"10.1016\/j.jconrel.2011.11.019_bb0015","first-page":"32","article-title":"New findings in the pharmacokinetic, metabolic, and drug-resistance aspects of mitomycin C","volume":"15","author":"Dorr","year":"1988","journal-title":"Semin. Oncol."},{"issue":"2","key":"10.1016\/j.jconrel.2011.11.019_bb0020","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1006\/jsre.1998.5481","article-title":"The importance of DT-diaphorase in mitomycin C resistance in human colon cancer cell lines","volume":"80","author":"Lambert","year":"1998","journal-title":"J. Surg. Res."},{"issue":"1","key":"10.1016\/j.jconrel.2011.11.019_bb0025","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/1097-0142(19850101)55:1<47::AID-CNCR2820550108>3.0.CO;2-#","article-title":"Renal complications of mitomycin C therapy with special reference to the total dose","volume":"55","author":"Valavaara","year":"1985","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.jconrel.2011.11.019_bb0030","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1158\/1078-0432.CCR-05-1547","article-title":"Reduced toxicity and superior therapeutic activity of a mitomycin C lipid-based prodrug incorporated in pegylated liposomes","volume":"12","author":"Gabizon","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2011.11.019_bb0035","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1021\/jo00296a082","article-title":"Development of a drug-release strategy based on the reductive fragmentation of benzyl carbamate disulfides","volume":"55","author":"Senter","year":"1990","journal-title":"J. Org. Chem."},{"issue":"7\u20138","key":"10.1016\/j.jconrel.2011.11.019_bb0040","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1080\/10611860701499946","article-title":"Antitumor activity of new liposomal prodrug of mitomycin C in multidrug resistant solid tumor: insights of the mechanism of action","volume":"15","author":"Zalipsky","year":"2007","journal-title":"J. Drug Target."},{"issue":"3","key":"10.1016\/j.jconrel.2011.11.019_bb0045","first-page":"297","article-title":"Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential","volume":"1","author":"Immordino","year":"2006","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2011.11.019_bb0050","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1146\/annurev.pharmtox.41.1.261","article-title":"Properties and biological activities of thioredoxins","volume":"41","author":"Powis","year":"2001","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"4","key":"10.1016\/j.jconrel.2011.11.019_bb0055","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.coph.2007.04.003","article-title":"Thioredoxin signaling as a target for cancer therapy","volume":"7","author":"Powis","year":"2007","journal-title":"Curr. Opin. Pharmacol."},{"issue":"3","key":"10.1016\/j.jconrel.2011.11.019_bb0060","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/S0021-9258(18)70226-3","article-title":"Phosphorus assay in column chromatography","volume":"234","author":"Bartlett","year":"1959","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.jconrel.2011.11.019_bb0065","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2165\/00003088-200342050-00002","article-title":"Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies","volume":"42","author":"Gabizon","year":"2003","journal-title":"Clin. Pharmacokinet."},{"issue":"1","key":"10.1016\/j.jconrel.2011.11.019_bb0070","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.2042-7158.1980.tb12840.x","article-title":"Mitomycin C-dextran conjugate: a novel high molecular weight pro-drug of mitomycin C","volume":"32","author":"Kojima","year":"1980","journal-title":"J. Pharm. Pharmacol."},{"issue":"1","key":"10.1016\/j.jconrel.2011.11.019_bb0075","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1248\/bpb.16.48","article-title":"Pharmacokinetic characteristics and antitumor activity of the N-succinyl-chitosan-mitomycin C conjugate and the carboxymethyl-chitin-mitomycin C conjugate","volume":"16","author":"Song","year":"1993","journal-title":"Biol. Pharm. Bull."},{"issue":"5","key":"10.1016\/j.jconrel.2011.11.019_bb0080","first-page":"351","article-title":"Polymeric prodrugs of mitomycin C designed for tumour tropism and sustained activation","volume":"11","author":"Seymour","year":"1996","journal-title":"Anticancer Drug Des."},{"issue":"12","key":"10.1016\/j.jconrel.2011.11.019_bb0085","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1002\/jps.2600751210","article-title":"Characterization of liposomes and an emulsion containing mitomycin C or lipophilic mitomycin C prodrugs","volume":"75","author":"Sasaki","year":"1986","journal-title":"J. Pharm. Sci."},{"issue":"8","key":"10.1016\/j.jconrel.2011.11.019_bb0090","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1248\/cpb.36.3060","article-title":"Liposomal sustained-release delivery systems for intravenous injection. I. Physicochemical and biological properties of newly synthesized lipophilic derivatives of mitomycin C","volume":"36","author":"Tokunaga","year":"1988","journal-title":"Chem. Pharm. Bull.(Tokyo)"},{"issue":"9","key":"10.1016\/j.jconrel.2011.11.019_bb0095","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.1248\/cpb.36.3557","article-title":"Liposomal sustained-release delivery systems for intravenous injection. II. Design of liposome carriers and blood disposition of lipophilic mitomycin C prodrug-bearing liposomes","volume":"36","author":"Tokunaga","year":"1988","journal-title":"Chem. Pharm. Bull.(Tokyo)"},{"issue":"9","key":"10.1016\/j.jconrel.2011.11.019_bb0100","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1248\/cpb.36.3565","article-title":"Liposomal sustained-release delivery systems for intravenous injection. III. Antitumor activity of lipophilic mitomycin C prodrug-bearing liposomes","volume":"36","author":"Tokunaga","year":"1988","journal-title":"Chem. Pharm. Bull.(Tokyo)"},{"issue":"21","key":"10.1016\/j.jconrel.2011.11.019_bb0105","doi-asserted-by":"crossref","first-page":"4840","DOI":"10.1016\/j.biomaterials.2011.03.040","article-title":"Hyaluronan-grafted particle clusters loaded with Mitomycin C as selective nanovectors for primary head and neck cancers","volume":"32","author":"Bachar","year":"2011","journal-title":"Biomaterials"},{"issue":"2","key":"10.1016\/j.jconrel.2011.11.019_bb0110","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s00280-005-0151-z","article-title":"Folate receptor specific anti-tumor activity of folate\u2013mitomycin conjugates","volume":"58","author":"Reddy","year":"2006","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"5933","key":"10.1016\/j.jconrel.2011.11.019_bb0115","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1126\/science.1171362","article-title":"Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer","volume":"324","author":"Olive","year":"2009","journal-title":"Science"},{"issue":"6 Suppl 13","key":"10.1016\/j.jconrel.2011.11.019_bb0120","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1053\/j.seminoncol.2004.08.001","article-title":"Advantages of liposomal delivery systems for anthracyclines","volume":"31","author":"Allen","year":"2004","journal-title":"Semin. Oncol."},{"issue":"8","key":"10.1016\/j.jconrel.2011.11.019_bb0125","first-page":"2281","article-title":"Thioredoxin reductase, a redox-active selenoprotein, is secreted by normal and neoplastic cells: presence in human plasma","volume":"60","author":"Soderberg","year":"2000","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.jconrel.2011.11.019_bb0130","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.semcancer.2006.10.009","article-title":"The thioredoxin system in cancer","volume":"16","author":"Arner","year":"2006","journal-title":"Semin. Cancer Biol."},{"issue":"10","key":"10.1016\/j.jconrel.2011.11.019_bb0135","first-page":"3087","article-title":"Thioredoxin expression is associated with lymph node status and prognosis in early operable non-small cell lung cancer","volume":"7","author":"Kakolyris","year":"2001","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.jconrel.2011.11.019_bb0140","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S0022-2143(03)00068-4","article-title":"Increased expression of thioredoxin-1 in human colorectal cancer is associated with decreased patient survival","volume":"142","author":"Raffel","year":"2003","journal-title":"J. Lab. Clin. Med."},{"issue":"2","key":"10.1016\/j.jconrel.2011.11.019_bb0145","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.lab.2005.09.001","article-title":"The antitumor thioredoxin-1 inhibitor PX-12 (1-methylpropyl 2-imidazolyl disulfide) decreases thioredoxin-1 and VEGF levels in cancer patient plasma","volume":"147","author":"Baker","year":"2006","journal-title":"J. Lab. Clin. Med."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365911010728?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365911010728?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,12,18]],"date-time":"2021-12-18T11:39:11Z","timestamp":1639827551000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365911010728"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["S0168365911010728"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2011.11.019","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6]]}}}